GV.PA stock jumped after-hours on 04 Mar 2026, rising 5.88% to trade around EUR 0.0018 on EURONEXT. The move came with heavy turnover of 38,489,238 shares, more than double the 14,217,513 average volume, underlining why the name is among today’s most active small caps. Traders reacted to intraday swings between EUR 0.0015 and EUR 0.0020, while the market cap stands at EUR 693,191. We summarise the drivers, valuations, Meyka AI technical grade, and a clear short- and medium-term outlook for active traders.

GV.PA stock intraday moves and volume

Genomic Vision SA (GV.PA) closed the regular session at EUR 0.0017 and traded as high as EUR 0.0020 after-hours. Volume hit 38,489,238 versus an average of 14,217,513, a relative volume of 2.71, which is consistent with most-active behaviour and increased retail and speculative interest.

High relative volume with small market capitalisation (EUR 693,191) magnifies price swings. For active traders, today’s range and a day high of EUR 0.0020 are key levels for short-term entries and stops.

Valuation and financial metrics for GV.PA stock

Genomic Vision reports EPS of -0.11 and a negative PE of -0.02, reflecting losses. Price averages are weak: 50-day average EUR 0.00484 and 200-day average EUR 0.01399, both well above today’s price.

Key ratios: price-to-sales 0.47, enterprise value-to-sales 1.60, and current ratio 0.91. Cash per share is 0.00557 and shareholders’ equity per share is negative -0.00944, highlighting capital weakness and dilution risk.

Technical snapshot, levels and Meyka AI grade

Short-term technicals show a steep downtrend: 3-month change -77.78% and YTD -95.96%, leaving GV.PA in deep discount territory versus its one-year high EUR 0.094. Immediate support sits near the year low EUR 0.0014, resistance at recent highs EUR 0.0020 and moving averages near EUR 0.00484 (50-day).

Meyka AI rates GV.PA with a score out of 100: 62.57 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational only and not financial advice.

Catalysts, sector context and risks for GV.PA stock

Catalysts include commercial rollouts for FiberVision systems and partnerships such as Quest Diagnostics, plus research agreements with Institut Pasteur. The Healthcare sector average PE stands near 30.34, so GV.PA’s valuation profile is not comparable to large peers; it is a technology-heavy diagnostics microcap.

Risks are high: negative operating margins, long inventory cycles, and potential dilution. Interest coverage is negative -8.98, and working capital shows a shortfall of EUR 361,000, underscoring financing risk for development-led companies.

Trading setup for most-active session participants

Traders should treat GV.PA as a high-volatility, high-risk microcap. Use tight position sizing, define stop-loss near EUR 0.0014, and consider profit targets at intraday resistance EUR 0.0020 and swing target EUR 0.0050. Watch for continued volume above 14,217,513 to confirm follow-through.

Options are not available; liquidity is driven by shares. For short-term scalps, the intraday range and the next visible resistance are the primary anchors for trade management.

Outlook and catalysts to watch in GV.PA newsflow

Near term, look for corporate updates on product shipments, revenue recognition events, or capital raises. Any confirmation of recurring revenue from FiberVision or new partnerships could re-rate the stock. Conversely, further dilution or missed milestones would likely push the price lower given current cash and negative margins.

Sector performance and healthcare diagnostics demand will matter. Watch broader Healthcare flows and news from partners like Quest Diagnostics for directional cues.

Final Thoughts

GV.PA stock traded higher after-hours on 04 Mar 2026, rising 5.88% to EUR 0.0018 on heavy volume, a sign of active trading rather than a change in fundamentals. The company shows negative EPS -0.11, negative PE, a weak current ratio 0.91, and negative equity per share, which keeps the risk profile elevated. For traders, today’s action highlights volatility and short-term opportunities. Meyka AI’s forecast model projects a 12-month target of EUR 0.0100, versus the current price EUR 0.0018, implying a potential upside of 455.56%. We add a conservative near-term price target of EUR 0.0050 and a bullish scenario target of EUR 0.0200. Forecasts are model-based projections and not guarantees. Active traders should pair strict risk controls with any position, and longer-term investors must monitor cash raises, revenue traction, and execution against clinical and commercial milestones. Meyka AI provides this analysis as an AI-powered market analysis platform

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.